- Home
- AVBP vs REPL Comparison
AVBP vs REPL Comparison
Compare AVBP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVBP
- REPL
- Stock Information
- Founded
- AVBP 2021
- REPL 2015
- Country
- AVBP United States
- REPL United States
- Employees
- AVBP N/A
- REPL N/A
- Industry
- AVBP
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- AVBP
- REPL Health Care
- Exchange
- AVBP NYSE
- REPL Nasdaq
- Market Cap
- AVBP 862.8M
- REPL 757.8M
- IPO Year
- AVBP 2024
- REPL 2018
- Fundamental
- Price
- AVBP $21.63
- REPL $11.09
- Analyst Decision
- AVBP Strong Buy
- REPL Strong Buy
- Analyst Count
- AVBP 8
- REPL 7
- Target Price
- AVBP $38.38
- REPL $20.83
- AVG Volume (30 Days)
- AVBP 484.4K
- REPL 1.3M
- Earning Date
- AVBP 08-13-2025
- REPL 08-07-2025
- Dividend Yield
- AVBP N/A
- REPL N/A
- EPS Growth
- AVBP N/A
- REPL N/A
- EPS
- AVBP N/A
- REPL N/A
- Revenue
- AVBP N/A
- REPL N/A
- Revenue This Year
- AVBP $85.82
- REPL N/A
- Revenue Next Year
- AVBP N/A
- REPL N/A
- P/E Ratio
- AVBP N/A
- REPL N/A
- Revenue Growth
- AVBP N/A
- REPL N/A
- 52 Week Low
- AVBP $15.47
- REPL $6.44
- 52 Week High
- AVBP $36.37
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- AVBP 47.74
- REPL 68.18
- Support Level
- AVBP $19.71
- REPL $9.26
- Resistance Level
- AVBP $22.32
- REPL $9.90
- Average True Range (ATR)
- AVBP 1.32
- REPL 0.59
- MACD
- AVBP -0.20
- REPL 0.14
- Stochastic Oscillator
- AVBP 31.89
- REPL 91.56
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.